Download full report with analyst certification and important disclosures
Feb 26 2026, 07:10 GMT
CVS Group
H1 2026 results
- Sectors : Pharma and healthcare
- Companies : CVS Group
DAVY VIEW
CVS had a trading statement in January, which provided some of its H1 results. Organic top line growth was 2.7% despite weak consumer spending in the UK. The company expects to achieve consensus EBITDA in FY2026. We will look to increase our estimates on interest and tax leading us to lower EPS forecasts.
